Clinical Solutions Vice President (Remote) Job description: The Medicare Part D pharmacy programs manager manages the coordination of benefits in the pharmacy program with Medicare Part D plans,...

Formulary design recommendations help create competition to drive savings, provide optionality to meet unique client needs.

If you think about the rise of specialty drugs as a Category 5 hurricane, and the growth of gene therapies as an undersea earthquake, you can see the rising tsunami of drug spend looking to sweep...

In this special episode of the Pharmacy Friends podcast, “Live at Specialty Summit ’24 – Connect. Elevate. Transform.,” we are on the road in New York City at our 21st annual Specialty Summit. More...

The SIU promotes safety to prevent fraud, waste and abuse schemes

Clinical Solutions VP (Remote) Looking for your next career move and want to help Prime Therapeutics (Prime) put more care in health care? Check out the Prime Careers Spotlight, a monthly roundup...

Recent webinar featuring Prime Therapeutics experts shares some of the latest breakthrough therapies — including ADCs, BiTes and CAR-T treatments — and regulatory changes and market shifts that are...

Dinesh Kandanchatha joined the organization July 1.

Parikh, director of medical pharmacy strategy at Prime/MRx, shares the latest on interchangeable biosimilars

Prime Therapeutics/Magellan Rx Management's signature event featured the hottest topics in specialty drug management and more

Prime Therapeutics offers first-of-its-kind digital utilization management solution that pairs biomarker testing with targeted therapy drug selection

New report highlights value-based contract solution and analysis of top 10 drug classes impacting Medicaid pharmacy net trend

As the efficacy and cost of these therapies become clear, so is the need for thoughtful managed care strategies, according to Prime Therapeutics thought leaders

Insights from Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Prime works to simplify medication management and support patients with migraine, making migraine treatment less of a pain point

Cover image for Drug Approvals Monthly Update: September 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty...

Cover image for Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty...

Lead author David Eckwright shares more about the study “Real-World Extended Dosing Assessment for Eye(s) new to Faricimab-svoa Therapy.”

Cover AMCP Prime Therapeutics /amcp-nexus-2024-research-posters 10 research posters presented by Prime at AMCP Nexus 2024 covers topics like GLP-1 obesity research, health equity initiatives, and...

Cover image for 8 research posters presented by Prime at the 2024 AMCP Annual Meeting 2024 AMCP Annual Meeting Prime Therapeutics /2024-amcp-annual-meeting-research-posters 8 research posters...

Constant communication across the supply chain limits disruption when a drug is unavailable

This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.

This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.

Drug Approvals Quarterly Update: July 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process. Prime...

Prime’s Special Investigations Unit is specially trained to protect patients and providers throughout the health care continuum

A strategic deep dive into the latest trend report from Prime Therapeutics reveals how oncology spend is evolving across benefits and what it means for cancer care management

Jessica Johnson, clinical consultant at Prime Therapeutics, shares some ways to avoid common fraud schemes

Cover image for FDA Decisions Expected_February 2025 Drug pipeline for February 2025 Prime Therapeutics /fda-decisions-expected-february-2025 About Prime Therapeutics Prime Therapeutics logo Prime...

Event features Pat Gleason, AVP, health outcomes at Prime Therapeutics

Home Other Navigation Pharmacy + Providers Pharmacy Credentialing Important information Updated Insurance Coverage Information To submit a renewal, submit your updated certificate of insurance to...

Cover image for FDA Decisions Expected: November 2024 Drug pipeline for November 2024 Prime Therapeutics /fda-decisions-expected-november-2024 Prime Therapeutics’ FDA Decisions Expected outlines...

Commercial information Your Choices Regarding Your Information You may have the following rights with respect to your personal information, subject to applicable exceptions: Right to access. You...

Home Newsroom Custom Content Publications High Cost Therapy Profile High-Cost Therapy Profile: September 2024 Oncology/ cellular therapy Obecabtagene autoleucel Intravenous (IV) Autolus Proposed...

A female-presenting person speaks at a legislative building, wearing a green blazer and glasses. George Van Antwerp breaks down how Prime is poised to drive affordability in drug pricing Alex Cook...

These new solutions reflect Prime's distinctive conflict-free approach to the prescription drug supply chain model.

Pharmacy Friends In the latest episode of the “Pharmacy Friends” podcast, learn the latest insights on legislative trends, cutting-edge drug therapies and more from the 22nd annual event Alex Cook...

New Biosimilars First Generic Drug Launches Oct. 25, 2024 - sulopenem etzadroxil and probenecid (Orlynvah) The FDA has approved Iterum’s Orlynvah for the treatment of uncomplicated urinary tract...

Upgrade provides streamlined patient support and enhanced digital engagement for data-driven, holistic care

FDA approved BiTEs: Brand name Generic name Route Target Indication First FDA indication approval date Blincyto Blinatumomab IV anti-CD19 / anti-CD3 Acute lymphocytic leukemia 12/3/2014 Columvi...

Based on the clinical trial, there are certain expectations for how long patients can anticipate seeing the benefits of treatment. The median duration of response was 11.6 months (95% CI, 4.4 to...